Abstract 1153: IL-4 depletion leads to the improvement of CART cell therapy
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-1153
Abstract: While chimeric antigen receptor T-cell therapy targeting CD19 (CART19) has shown remarkable success in the treatment of hematological malignancies, the durable response rates remain approximately 40% and there are limited solutions for CART cell therapy… read more here.
Keywords: cell therapy; cell; cart cell; cart19 ... See more keywords
Abstract 6813: Immunosuppressive monocytes suppress CART19 functions through modulation of the IL-1 pathway
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-6813
Abstract: CD19-directed chimeric antigen receptor T (CART19) cell therapy has shown remarkable outcomes in B cell malignancies and was FDA approved in multiple indications, but durable remissions are limited to ~40%. Inhibitory myeloid cells in the… read more here.
Keywords: jeko; jeko cart19; like macrophages; cell ... See more keywords
Efficient Gene Editing of CART Cells with CRISPR-Cas12a for Enhanced Antitumor Efficacy
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-141115
Abstract: Chimeric antigen receptor T (CART) cells are engineered with an artificial receptor which redirects T cells to recognize cancer cells expressing a particular surface antigen. CART cell therapy has been astonishingly successful at eradicating certain… read more here.
Keywords: cart19; cas9; research funding; cart cells ... See more keywords